Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
NCT00651833
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
DRUG:
S-1
Sponsor
Taiho Oncology, Inc.
Collaborators
[object Object]
[object Object]